AR054259A1 - Vacuna contra virus de papiloma humano (hpv) - Google Patents
Vacuna contra virus de papiloma humano (hpv)Info
- Publication number
- AR054259A1 AR054259A1 AR20060101619A ARP060101619A AR054259A1 AR 054259 A1 AR054259 A1 AR 054259A1 AR 20060101619 A AR20060101619 A AR 20060101619A AR P060101619 A ARP060101619 A AR P060101619A AR 054259 A1 AR054259 A1 AR 054259A1
- Authority
- AR
- Argentina
- Prior art keywords
- hpv
- protein
- vaccine
- immunogenic fragment
- against human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un procedimiento para la prevencion de infeccion y/o enfermedad por HPV, comprendiendo el procedimiento suministrar una primera vacuna contra HPV que comprende una proteína L1 o fragmento inmunogénico de la misma de al menos HPV 16 y HPV18, y una segunda vacuna contra HPV que no comprende los componentes L1 de HPV 16 y HPV 18 de la primera vacuna, y que comprende la segunda vacuna una proteína L1 o fragmento inmunogénico de la misma de al menos un tipo de HPV oncogénico diferente, done la primera y segunda vacunas pueden suministrarse en cualquier orden y el suministro está separado por un intervalo de tiempo adecuado. Reivindicacion 1: Uso de una proteína L1 de virus de papiloma humano o fragmento inmunogénico de la misma de un primer tipo de HPV en la preparacion de un medicamento para reforzar una respuesta inmune previamente provocada por una proteína L1 de virus de papiloma humano o fragmento inmunogénico dela misma de un tipo de HPV diferente. Reivindicacion 20: Una composicion de vacuna que comprende una combinacion de una proteína L1 de HPV 31 o fragmento inmunogénico de la misma y una proteína L1 de HPV 45 o un fragmento inmunogénico de la misma, no conteniendo la vacuna proteína L1 de HPV 16 o HPV 18 o fragmentos inmunogénicos de la misma. Reivindicacion 22: Un kit que comprende una primera y segunda composiciones de vacuna de acuerdo con la reivindicacion 11.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67482905P | 2005-04-26 | 2005-04-26 | |
GB0509010A GB0509010D0 (en) | 2005-05-03 | 2005-05-03 | Vaccine |
PCT/EP2005/006461 WO2005123125A1 (en) | 2004-06-16 | 2005-06-14 | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054259A1 true AR054259A1 (es) | 2007-06-13 |
Family
ID=36992675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20060101619A AR054259A1 (es) | 2005-04-26 | 2006-04-24 | Vacuna contra virus de papiloma humano (hpv) |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090181052A1 (es) |
EP (1) | EP1877086A2 (es) |
JP (1) | JP2008539184A (es) |
KR (1) | KR20080005585A (es) |
AR (1) | AR054259A1 (es) |
AU (1) | AU2006239422A1 (es) |
CA (1) | CA2606092A1 (es) |
EA (1) | EA013326B1 (es) |
MX (1) | MX2007013472A (es) |
NO (1) | NO20075194L (es) |
SG (1) | SG159525A1 (es) |
WO (1) | WO2006114312A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
CA2732436C (en) * | 2008-07-31 | 2018-01-16 | Glaxosmithkline Biologicals S.A. | Vaccine against hpv |
EP2444103B1 (en) * | 2009-06-19 | 2017-12-20 | Eyegene Inc. | Vaccine for cervical cancer |
RU2610174C2 (ru) | 2011-06-24 | 2017-02-08 | Мерк Шарп И Доум Корп. | Вакцинные составы против вируса папилломы человека (hpv), содержащие алюминиевый адъювант, и способы их получения |
CR20220395A (es) | 2020-02-14 | 2022-10-27 | Merck Sharp & Dome Llc | Vacuna contra hpv |
US20230048144A1 (en) | 2021-08-06 | 2023-02-16 | Merck Sharp & Dohme Llc | Hpv vaccine |
CA3229064A1 (en) | 2021-08-19 | 2023-02-23 | Andrew Bett | Thermostable lipid nanoparticle and methods of use thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US6908613B2 (en) * | 2000-06-21 | 2005-06-21 | Medimmune, Inc. | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
GB0105606D0 (en) * | 2001-03-07 | 2001-04-25 | Cantab Pharmaceuticals Res Ltd | Immunogens and vaccines and their preparation and use |
GB0206360D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
ATE503492T1 (de) * | 2002-12-20 | 2011-04-15 | Glaxosmithkline Biolog Sa | Verwendung von hpv16 und hpv18 vlps als vakzine gegen eine oder mehrere onkogene hpv des typus 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 |
MY140664A (en) * | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
-
2006
- 2006-04-24 WO PCT/EP2006/003918 patent/WO2006114312A2/en active Application Filing
- 2006-04-24 KR KR1020077027497A patent/KR20080005585A/ko not_active Application Discontinuation
- 2006-04-24 MX MX2007013472A patent/MX2007013472A/es unknown
- 2006-04-24 EP EP06724609A patent/EP1877086A2/en not_active Ceased
- 2006-04-24 CA CA002606092A patent/CA2606092A1/en not_active Abandoned
- 2006-04-24 AR AR20060101619A patent/AR054259A1/es not_active Application Discontinuation
- 2006-04-24 EA EA200702079A patent/EA013326B1/ru not_active IP Right Cessation
- 2006-04-24 SG SG201000794-6A patent/SG159525A1/en unknown
- 2006-04-24 AU AU2006239422A patent/AU2006239422A1/en not_active Abandoned
- 2006-04-24 US US11/912,687 patent/US20090181052A1/en not_active Abandoned
- 2006-04-24 JP JP2008508156A patent/JP2008539184A/ja active Pending
-
2007
- 2007-10-11 NO NO20075194A patent/NO20075194L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200702079A1 (ru) | 2008-04-28 |
MX2007013472A (es) | 2008-04-02 |
EP1877086A2 (en) | 2008-01-16 |
SG159525A1 (en) | 2010-03-30 |
US20090181052A1 (en) | 2009-07-16 |
EA013326B1 (ru) | 2010-04-30 |
JP2008539184A (ja) | 2008-11-13 |
WO2006114312A2 (en) | 2006-11-02 |
NO20075194L (no) | 2008-01-18 |
WO2006114312A3 (en) | 2007-04-05 |
KR20080005585A (ko) | 2008-01-14 |
CA2606092A1 (en) | 2006-11-02 |
AU2006239422A1 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
CY1120347T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
AR040204A1 (es) | Composicion de vacuna meningococica multivalente | |
ECSP045300A (es) | Antígenos virales | |
BRPI0510430A (pt) | composições e métodos para vacinação mucosal | |
NO20082472L (no) | Vaksinesammensetninger omfattende en saponin adjuvant | |
WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
AR055603A1 (es) | Vacuna contra la infeccion por virus del dengue | |
MY169275A (en) | Method of immunization against the four serotypes of dengue | |
WO2007052155A3 (en) | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant | |
DE60024112D1 (de) | Influenzavirus-impfstoffzusammensetzung | |
UY26724A1 (es) | Métodos y composiciones para tratar el virus de la hepatitis c | |
ECSP055869A (es) | Vacuna hpv-16 y -18 l1 vlp | |
WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
AR071741A1 (es) | Vacunas contra la malaria | |
HRP20100473T1 (hr) | Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c | |
DE60336225D1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
BRPI0516314A (pt) | uso de hiv inteiro e método de tratamento de um indivìduo cronicamente infectado com hiv | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
BR112022015313A2 (pt) | Vacina de hpv | |
AR049354A1 (es) | VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN | |
WO2006024240A3 (es) | Composición vacunal contra el virus de la hepatitis c. | |
CO6341567A2 (es) | Vacuna contra el virus de papiloma humano |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |